Prostate inflammation and its potential impact on prostate cancer: A current review

Journal of Cellular Biochemistry

Volumn 103, Issue 5, 2008, Pages 1344-1353

  Haverkamp, Jessica ^a,b   Charbonneau, Bridget ^a   Ratliff, Timothy L ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Inflammation; Mouse model; POET 3; Prostate; Prostate cancer; Prostatitis

Indexed keywords

CHEMOKINE; CYTOKINE; GROWTH FACTOR;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CAUSAL ATTRIBUTION; CELL INFILTRATION; DISEASE ASSOCIATION; IMMUNE RESPONSE; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SEXUALLY TRANSMITTED DISEASE;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATIC NEOPLASMS; PROSTATITIS;

ANIMALIA;

EID: 41749083284     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21536     Document Type: Review

References (52)

1. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, Agrez MV, Mok S, Baker MS. 2002. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 23:237-244.
2. American Cancer Society. 2007. Cancer facts and figures. Atlanta: American Cancer Society.
3. Ames BN, Gold LS, Willett WC. 1995. The causes and prevention of cancer. Proc Natl Acad Sci USA 92:5258-5265.
4. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA. 2007. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 178:1268-1276.
5. Balkwill F. 2006. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25:409-416.
6. Bostwick DG, de la Roza G, Dundore P, Corica FA, Iczkowski KA. 2003. Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate 55: 187-193.
7. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. 1999. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38:199-207.
8. Collins MM, Stafford RS, O'Leary MP, Barry MJ. 1998. How common is prostatitis? A national survey of physician visits. J Urol 159:1224-1228.
9. Culig Z, Steiner H, Bartsch G, Hobisch A. 2005. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95:497-505.
10. Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF. 2005. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 202:361-370.
11. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. 1999. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 155:1985-1992.
12. Dennis LK, Lynch CF, Tomer JC. 2002. Epidemiologic association between prostatitis and prostate cancer. Urology 60:78-83.
13. Elkahwaji JE, Zhong W, Hopkins WJ, Bushman W. 2007. Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis. Prostate 67:14-21.
14. Elliott RL, Blobe GC. 2005. Role of transforming growth factor Beta in human cancer. J Clin Oncol 23:2078-2093.
15. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. 2003. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4:223-238.
16. Fedida S, Fishman D, Suzlovich Z, Argov S, Friger M, Oren L, Segal S, Sion-Vardy N. 2007. Impaired access of lymphocytes to neoplastic prostate tissue is associated with neoangiogenesis in the tumour site. Br J Cancer 96:980-985.
17. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. 1998. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51:161-167.
18. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183: 2593-2603.
19. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. 1996. Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096-4102.
20. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. 2000. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6:2104-2119.
21. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. 1998. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:3513-3521.
22. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. 1996. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2:1255-1261.
23. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA. 2000. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6:2295-2308.
24. Lu S, Dong Z. 2006. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells. Prostate 66:996-1004.
25. Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, Gudkov AV. 2004. Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 101:7112-7117.
26. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z, Zhang J. 2006. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66:1311-1318.
27. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J. 2007. CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101:676-685.
28. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S. 2006. The influence of chronic inflammation in prostatic carcinogenesis: A 5-year followup study. J Urol 176:1012-1016.
29. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA. 2004. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91:541-543.
30. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED. 2001. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 98:14565-14570.
31. Michalaki V, Syrigos K, Charles P, Waxman J. 2004. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90:2312-2316.
32. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P. 2006. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177:7398-7405.
33. Motrich RD, Maccioni M, Molina R, Tissera A, Olmedo J, Riera CM, Rivero VE. 2005. Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol 116:149-157.
34. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. 2004. The role of inflammation in the pathogenesis of prostate cancer. J Urol 172:S6-S11, discussion S11-2.
35. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. 2003. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101:2620-2627.
36. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG. 2003. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22:4314-4332.
37. Peluso I, Fantini MC, Fina D, Caruso R, Boirivant M, MacDonald TT, Pallone F, Monteleone G. 2007. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 178:732-739.
38. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. 2004. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 173:6098-6108.
39. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M. 1999. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines. J Immunol 163:130-136.
40. Sari A, Serel TA, Candir O, Ozturk A, Kosar A. 1999. Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma. BJU Int 84:851-853.
41. Scott KA Arnott CH, Robinson SC, Moore RJ, Thompson RG, Marshall JF, Balkwill FR. 2004. TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene 23:6954-6966.
42. Siegall CB, Schwab G, Nordan RP, FitzGerald DJ, Pastan I. 1990. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 50:7786-7788.
43. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ. 2003. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56:171-182.
44. Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Bottinger EP, Danielpour D, Wakefield LM. 1999. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 59:4834-4842.
45. Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM. 2001. AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 92:641-650.
46. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA. 2005. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64:40-49.
47. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100:2645-2650.
48. Wang JM, Taraboletti G, Matsushima K, Van Damme J, Mantovani A. 1990. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun 169:165-170.
49. Wang W, Bergh A, Damber JE. 2004. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61: 60-72.
50. Wang W, Bergh A, Damber JE. 2005. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11:3250-3256.
51. Yano H, Kinuta M, Tateishi H, Nakano Y, Matsui S, Monden T, Okamura J, Sakai M, Okamoto S. 1999. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer 2:26-32.
52. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Akira S, Kotol PF, Glass CK, Rosenfeld MG, Rose DW. 2006. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124:615-629.